Related Experiment Videos
Update on Kaposi's Sarcoma: A Gammaherpesvirus- induced Malignancy
Pallavi P. Kumar1, Richard F. Little, Robert Yarchoan
1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1868, Building 10, Room 10S255, Bethesda, MD 20892-1868, USA. ryln@nih.gov
Current Infectious Disease Reports
|January 15, 2003
Summary
Kaposi
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Kaposi's sarcoma (KS) is a visible manifestation of the AIDS epidemic.
- The discovery of Kaposi's sarcoma-associated herpesvirus (KSHV) has advanced understanding of KS pathogenesis.
- Highly active antiretroviral therapy (HAART) has significantly impacted KS incidence and progression.
Purpose of the Study:
- To review recent advances in Kaposi's sarcoma epidemiology and pathogenesis.
- To discuss current Kaposi's sarcoma treatments.
- To explore emerging therapeutic strategies for Kaposi's sarcoma.
Main Methods:
- Literature review of recent advances in Kaposi's sarcoma research.
- Analysis of the impact of KSHV and HAART on Kaposi's sarcoma.
- Evaluation of novel therapeutic approaches including anti-angiogenesis strategies.
Main Results:
- KSHV is central to Kaposi's sarcoma pathogenesis.
- HAART has reduced Kaposi's sarcoma incidence and improved outcomes.
- Angiogenesis research offers potential for new Kaposi's sarcoma therapies.
Conclusions:
- Understanding KSHV and HAART has transformed Kaposi's sarcoma management.
- Future Kaposi's sarcoma therapies may target angiogenesis and viral factors.
- Multifaceted approaches are crucial for combating Kaposi's sarcoma.